2018 DCVAC/PCa (SOTIO) Drug Analysis - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: DCVAC/PCa" drug pipelines has been added to ResearchAndMarkets.com's offering.

DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells, which can then recognize and destroy prostate cancer tumor cells.

Key Topics Covered:

List of Figures

Figure 1: DCVAC/PCa for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of DCVAC/PCa for prostate cancer

Figure 3: Drug assessment summary of DCVAC/PCa for prostate cancer

Figure 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: DCVAC/PCa drug profile

Table 2: DCVAC/PCa Phase III trial in prostate cancer

Table 3: DCVAC/PCa Phase I/II data in prostate cancer

Table 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/slm633/2018_dcvacpca?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cancer Vaccines

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cancer Vaccines